197 related articles for article (PubMed ID: 21186845)
1. LC-MS based serum metabonomic analysis for renal cell carcinoma diagnosis, staging, and biomarker discovery.
Lin L; Huang Z; Gao Y; Yan X; Xing J; Hang W
J Proteome Res; 2011 Mar; 10(3):1396-405. PubMed ID: 21186845
[TBL] [Abstract][Full Text] [Related]
2. Hydrophilic interaction and reversed-phase ultraperformance liquid chromatography TOF-MS for serum metabonomic analysis of myocardial infarction in rats and its applications.
Tan G; Lou Z; Liao W; Dong X; Zhu Z; Li W; Chai Y
Mol Biosyst; 2012 Feb; 8(2):548-56. PubMed ID: 22037674
[TBL] [Abstract][Full Text] [Related]
3. Integrated ionization approach for RRLC-MS/MS-based metabonomics: finding potential biomarkers for lung cancer.
An Z; Chen Y; Zhang R; Song Y; Sun J; He J; Bai J; Dong L; Zhan Q; Abliz Z
J Proteome Res; 2010 Aug; 9(8):4071-81. PubMed ID: 20560663
[TBL] [Abstract][Full Text] [Related]
4. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
Xu G; Xiang CQ; Lu Y; Kang XN; Liao P; Ding Q; Zhang YF
Cancer Lett; 2009 Sep; 282(2):205-13. PubMed ID: 19362769
[TBL] [Abstract][Full Text] [Related]
5. (1)H NMR metabonomic analysis in renal cell carcinoma: a possible diagnostic tool.
Zira AN; Theocharis SE; Mitropoulos D; Migdalis V; Mikros E
J Proteome Res; 2010 Aug; 9(8):4038-44. PubMed ID: 20527959
[TBL] [Abstract][Full Text] [Related]
6. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
[TBL] [Abstract][Full Text] [Related]
7. Differential protein expressions in renal cell carcinoma: new biomarker discovery by mass spectrometry.
Siu KW; DeSouza LV; Scorilas A; Romaschin AD; Honey RJ; Stewart R; Pace K; Youssef Y; Chow TF; Yousef GM
J Proteome Res; 2009 Aug; 8(8):3797-807. PubMed ID: 19610612
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive urinary metabolomic approach for identifying kidney cancerr.
Kind T; Tolstikov V; Fiehn O; Weiss RH
Anal Biochem; 2007 Apr; 363(2):185-95. PubMed ID: 17316536
[TBL] [Abstract][Full Text] [Related]
9. Direct infusion mass spectrometry or liquid chromatography mass spectrometry for human metabonomics? A serum metabonomic study of kidney cancer.
Lin L; Yu Q; Yan X; Hang W; Zheng J; Xing J; Huang B
Analyst; 2010 Nov; 135(11):2970-8. PubMed ID: 20856980
[TBL] [Abstract][Full Text] [Related]
10. LC-MS-based serum metabolic profiling for genitourinary cancer classification and cancer type-specific biomarker discovery.
Lin L; Huang Z; Gao Y; Chen Y; Hang W; Xing J; Yan X
Proteomics; 2012 Aug; 12(14):2238-46. PubMed ID: 22685041
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive untargeted metabonomic analysis of human steatotic liver tissue by RP and HILIC chromatography coupled to mass spectrometry reveals important metabolic alterations.
García-Cañaveras JC; Donato MT; Castell JV; Lahoz A
J Proteome Res; 2011 Oct; 10(10):4825-34. PubMed ID: 21830829
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum-circulating RNA in patients with conventional renal cell cancer.
Feng G; Li G; Gentil-Perret A; Tostain J; Genin C
Anticancer Res; 2008; 28(1A):321-6. PubMed ID: 18383864
[TBL] [Abstract][Full Text] [Related]
13. RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer.
Chen Y; Zhang R; Song Y; He J; Sun J; Bai J; An Z; Dong L; Zhan Q; Abliz Z
Analyst; 2009 Oct; 134(10):2003-11. PubMed ID: 19768207
[TBL] [Abstract][Full Text] [Related]
14. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
[TBL] [Abstract][Full Text] [Related]
15. Identification of two new serum protein profiles for renal cell carcinoma.
Engwegen JY; Mehra N; Haanen JB; Schellens JH; Voest EE; Beijnen JH
Oncol Rep; 2009 Aug; 22(2):401-8. PubMed ID: 19578783
[TBL] [Abstract][Full Text] [Related]
16. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
Wechsel HW; Petri E; Bichler KH; Feil G
Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
[TBL] [Abstract][Full Text] [Related]
17. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry.
Yin P; Wan D; Zhao C; Chen J; Zhao X; Wang W; Lu X; Yang S; Gu J; Xu G
Mol Biosyst; 2009 Aug; 5(8):868-76. PubMed ID: 19603122
[TBL] [Abstract][Full Text] [Related]
18. Time-course changes in potential biomarkers detected using a metabonomic approach in Walker 256 tumor-bearing rats.
Shen G; Chen Y; Sun J; Zhang R; Zhang Y; He J; Tian Y; Song Y; Chen X; Abliz Z
J Proteome Res; 2011 Apr; 10(4):1953-61. PubMed ID: 21275377
[TBL] [Abstract][Full Text] [Related]
19. LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes.
Jing L; Guigonis JM; Borchiellini D; Durand M; Pourcher T; Ambrosetti D
Sci Rep; 2019 Oct; 9(1):15635. PubMed ID: 31666664
[TBL] [Abstract][Full Text] [Related]
20. Serum protein profiling to identify biomarkers for small renal cell carcinoma.
Xu G; Hou CR; Jiang HW; Xiang CQ; Shi N; Yuan HC; Ding Q; Zhang YF
Indian J Biochem Biophys; 2010 Aug; 47(4):211-8. PubMed ID: 21174948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
